Abstract: Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.

Abstract: Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.

Abstract: Provided are an antibody targeting NKG2A, a preparation method therefor and use thereof. Specifically, provided is a new mouse or humanized monoclonal antibody targeting NKG2A, and a method for preparing the monoclonal antibody. The monoclonal antibody can bind to an NKG2A antigen with high specificity, and has high affinity and significant activities such as anti-tumor activity.

Abstract: Disclosed is a pharmaceutical composition for treating hypercholesterolemia. The pharmaceutical composition includes a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients.

Abstract: Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.

Abstract: Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.

Abstract: Microcarriers, matrices and scaffolds for growing mammalian cells are provided which include copolymer particles and matrices comprising of polysaccharide-polyamine copolymers. The copolymeric particles and matrices have a pore size of at least 50 microns and permit the mammalian cells to grow both on an exterior surface of the particles and matrices and within an interior of the particles and matrices. Methods for making such microcarriers, matrices and scaffolds, and compositions are also provided. Methods for growing mammalian cells utilizing such microcarriers, matrices and scaffolds and compositions are also provided.

Abstract: Disclosed is a pharmaceutical composition for treating hyperuricemia (HUA). The pharmaceutical composition includes a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients.

Abstract: The invention is a polyoxymethylene film and a preparation method. The polyoxymethylene film comprises: 96 to 98 parts by weight of polyoxymethylene resin, 0.5 to 2 parts by weight of nucleating agent, 0.5 to 1 parts by weight of antioxidant, and 0.5 to 1 parts by weight of formaldehyde absorbent. In view of the high crystallinity and fast crystallization rate of polyoxymethylene, blown film process is used to directly blowing the molten mass extruded through a die of a screw extruder to form a blown film bubble. It is easy to form thin neck and easy to break when stretching, so the method is beneficial to form polyoxymethylene film, and has high processing efficiency, and is suitable for industrialization. Copolymerization unit —CH2—CH2—O— is introduced into the molecular chain of polyoxymethylene and its ratio is increased, thereby effectively reducing the crystallization rate of the materials and making it easier to form a film.

Abstract: A system for an electronic authentication client and a processing method thereof, and a system for electronic authentication and a method thereof are disclosed.

Abstract: Disclosed is a pharmaceutical composition for treating hyperuricemia (HUA). The pharmaceutical composition includes a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients.

Abstract: Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.

Abstract: Microcarriers, matrices and scaffolds for growing mammalian cells are provided which include copolymer particles and matrices comprising of polysaccharide-polyamine copolymers. The copolymeric particles and matrices have a pore size of at least 50 microns and permit the mammalian cells to grow both on an exterior surface of the particles and matrices and within an interior of the particles and matrices. Methods for making such microcarriers, matrices and scaffolds, and compositions are also provided. Methods for growing mammalian cells utilizing such microcarriers, matrices and scaffolds and compositions are also provided.

Abstract: Disclosed is a pharmaceutical composition for treating hypercholesterolemia. The pharmaceutical composition includes a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients.

Abstract: A system for an electronic authentication client and a processing method thereof, and a system for electronic authentication and a method thereof are disclosed.

Abstract: A blood vessel metal stent coating of amidoglucosan polysaccharide loaded with antibody comprises carrier material composed of chitosan and inartificial degradable acidic amidoglucosan polysaccharide and the effective dose of CD133 antibody loaded in the carrier material. The blood vessel metal stent coating is manufactured with self-assemble method to fix the CD133 antibody in the carrier material of the coating. The coating has good biocompatibility, water retention property, flexibility, flush resistance and bio-stability, and can specifically capture the vascular endothelial progenitor cells in human peripheral blood, and differentiate into vascular endothelial cells. The process would accelerate endothelialization to repair injured vessel caused and prevent restenosis and thrombosis efficiently.

Abstract: A blood vessel metal stent coating of amidoglucosan polysaccharide loaded with antibody comprises carrier material composed of chitosan and inartificial degradable acidic amidoglucosan polysaccharide and the effective dose of CD133 antibody loaded in the carrier material. The blood vessel metal stent coating is manufactured with self-assemble method to fix the CD133 antibody in the carrier material of the coating. The coating has good biocompatibility, water retention property, flexibility, flush resistance and bio-stability, and can specifically capture the vascular endothelial progenitor cells in human peripheral blood, and differentiate into vascular endothelial cells. The process would accelerate endothelialization to repair injured vessel caused and prevent restenosis and thrombosis efficiently.